Ajanta Pharma share price
You have to be logged in to add this to Watchlist.- ₹2,673.10(-0.40%)April 23, 2025 15:29:46 PM IST
- NSE
- BSE
- Vol : 65.83K (NSE + BSE)Last 20 day avg : 142.27 K
Ajanta Pharma is trading -0.40% lower at Rs 2,673.10 as compared to its last closing price. Ajanta Pharma has been trading in the price range of 2,737.95 & 2,659.00. Ajanta Pharma has given -8.63% in this year & 8.46% in the last 5 days. Ajanta Pharma has TTM P/E ratio 41.00 as compared to the sector P/E of 28.79.There are 10 analysts who have initiated coverage on Ajanta Pharma. There are 4 analysts who have given it a strong buy rating & 4 analysts have given it a buy rating. 1 analysts have given the stock a sell rating.The company posted a net profit of 232.88 Crores in its last quarter.Listed peers of Ajanta Pharma include Ipca Laboratories (1.23%), Laurus Labs (-0.18%), Ajanta Pharma (-0.40%).The Mutual Fund holding in Ajanta Pharma was at 15.13% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Ajanta Pharma was at 8.86% in 31 Mar 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Apr 23, 2025, 11:01 AM UTC
- Dividend YieldInline with the industry1.05Annual dividends as a percentage of the stock price.
- P/BHigher than historical values9.46The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values37.49Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates overvaluation4.18The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- BetaLow volatility0.41Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.01The debt-to-equity ratio, indicating a company's financial leverage.
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in December quarter by 3.71% from Rs 1146.13 crore to Rs 1105.15 crore, year-on-year
- The company has grown its December quarter profit by 10.88% from Rs 210.03 crore to Rs 232.88 crore, year-on-year
- The debt to equity of the company is lower than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 2,877.78
- R2
- 3,137.07
- R3
- 3,564.93
- S1
- 2,190.63
- S2
- 1,762.77
- S3
- 1,503.48
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Ipca Laboratories | Bullish | 1,462.00 | 1.23 | 37,157.69 | 55.07 | 5.7 | 0.28 | 9.80 |
| Laurus Labs | Bullish | 650.45 | -0.18 | 35,075.68 | 213.42 | 8.4 | 0.12 | 20.93 |
| Ajanta Pharma | Neutral | 2,673.10 | -0.40 | 33,453.56 | 41.24 | 9.46 | 2.02 | 0.66 |
| Suven Pharmaceuticals | Bullish | 1,201.15 | -2.59 | 30,731.01 | 101.08 | 14.92 | - | 1.04 |
| Piramal Pharma | Bullish | 223.65 | -0.40 | 29,650.36 | 479.90 | 3.69 | 0.05 | 32.89 |
Pledged found - Promoter(s) have pledged 12.61% of shares.- Promoter(s) have increased pledged shares to 11.17% from 12.61% earlier.
- Promoter(s) holds a high stake in the company at 66.26%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has decreased by 0.40 percentage points from previous quarter
- Mutual Funds holding has increased by 0.24 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-01-30 | Quarterly Results |
| 2024-10-28 | Quarterly Results |
| 2024-07-30 | Quarterly Results |
| 2024-05-02 | Audited Results & Buy Back of Shares |
| 2024-01-31 | Quarterly Results & 2nd Interim Dividend |
- IndustryBiotechnology & Drugs
- ISININE031B01049
- BSE Code532331
- NSE CodeAJANTPHARM
Ajanta Pharma is trading at 2673.10 as on Wed Apr 23 2025 09:59:46. This is -0.40% lower as compared to its previous closing price of 2683.95.
The market capitalization of Ajanta Pharma is 33453.56 Cr as on Wed Apr 23 2025 09:59:46.
The average broker rating on Ajanta Pharma is Buy. The breakup of analyst rating is given below -
- 4 analysts have given a strong buy rating
- 4 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 1 analysts have given a sell rating
- 1 analysts have given a strong sell rating
The 52 wk high for Ajanta Pharma is 3485.75 whereas the 52 wk low is 2022.05
Ajanta Pharma can be analyzed on the following key metrics -
- TTM P/E: 41.00
- Sector P/E: 28.79
- Dividend Yield: 1.05%
- D/E ratio: -
Ajanta Pharma reported a net profit of 816.17 Cr in 2024.
The Mutual Fund Shareholding was 15.13% at the end of 31 Mar 2025.